retatrutide benefits study Eli Lilly's shows promising weight loss results in phase 3 trial The future of metabolic science

INTRODUCTION THIS INFORMED CONSENT FOR GLP-1/GIP RECEPTOR AGONIST MEDICATIONS (THE "CONSENT") SETS FORTH THE TERMS AND POLICIES FOR THE CLINICAL SERVICES PROVIDED BY SUPERPOWER MEDICAL GROUP OF CA PC, A CALIFORNIA PROFESSIONAL MEDICAL CORPORATION, AND OTHER THIRD-PARTY MEDICAL GROUPS (THE "MEDICAL GROUPS") THROUGH THE ONLINE TECHNOLOGY PLATFORM ("PLATFORM" OR "SUPERPOWER PLATFORM"), WHICH IS OWNED AND OPERATED BY SUPERPOWER HEALTH, INC

J.RossiniA

They may recommend: Liver function tests based on clinical judgement and your overall risk profile Strategies to minimise gastrointestinal side effects Referral to diabetes specialist nurses for education on hypoglycaemia prevention Signposting to alcohol support services if appropriate When to contact your GP urgently : Seek medical advice promptly if you experience severe abdominal pain (stop your GLP-1 medication if pancreatitis is suspected), persistent vomiting preventing medication or fluid intake, signs of dehydration, or symptoms of hypoglycaemia that don't resolve with usual measures

Your gut motility drops